Allspring Global Investments Holdings LLC Buys 1,290 Shares of Smith & Nephew plc (NYSE:SNN)

Allspring Global Investments Holdings LLC boosted its stake in Smith & Nephew plc (NYSE:SNN) by 74.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,025 shares of the medical equipment provider’s stock after purchasing an additional 1,290 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Smith & Nephew were worth $94,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Raymond James & Associates boosted its position in Smith & Nephew by 172.1% during the third quarter. Raymond James & Associates now owns 128,854 shares of the medical equipment provider’s stock valued at $4,013,000 after acquiring an additional 81,500 shares during the last quarter. Blue Trust Inc. lifted its position in Smith & Nephew by 460.5% in the 3rd quarter. Blue Trust Inc. now owns 4,658 shares of the medical equipment provider’s stock valued at $145,000 after acquiring an additional 3,827 shares in the last quarter. Creative Planning lifted its position in Smith & Nephew by 28.6% in the 3rd quarter. Creative Planning now owns 62,319 shares of the medical equipment provider’s stock valued at $1,941,000 after acquiring an additional 13,845 shares in the last quarter. GAMMA Investing LLC lifted its position in Smith & Nephew by 160.0% in the 3rd quarter. GAMMA Investing LLC now owns 2,257 shares of the medical equipment provider’s stock valued at $70,000 after acquiring an additional 1,389 shares in the last quarter. Finally, Sanctuary Advisors LLC purchased a new stake in Smith & Nephew in the 2nd quarter valued at about $627,000. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on SNN shares. StockNews.com upgraded shares of Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research note on Monday, August 5th. Deutsche Bank Aktiengesellschaft downgraded shares of Smith & Nephew from a “buy” rating to a “hold” rating in a report on Friday.

Smith & Nephew Stock Performance

NYSE SNN opened at $25.28 on Tuesday. Smith & Nephew plc has a 52-week low of $23.65 and a 52-week high of $31.72. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51. The company has a market capitalization of $11.05 billion, a P/E ratio of 12.70, a P/E/G ratio of 1.10 and a beta of 0.85. The company has a fifty day moving average of $29.87 and a 200-day moving average of $27.85.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.